Our data show that NSCLC treatment with a combination of TGFβ and dasatinib results in up-regulation of BIM in cell lines where there is increase PARP cleavage (A549, PC-9 and H1944). This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.